Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company
- Details
- Category: Pfizer
Pfizer (NYSE: PFE) and Wyeth (NYSE: WYE) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The Boards of Directors of both companies have approved the combination.
Novartis launches Extavia®, the standard-of-care for relapsing forms of multiple sclerosis
- Details
- Category: Novartis
Novartis has announced the launch of Extavia®, a new version of the standard-of-care for relapsing forms of multiple sclerosis (MS), providing patients and physicians with an alternative option to help manage this devastating disease.
Foundation-laying ceremony for new R&D building at Roche Basel
- Details
- Category: Roche
At a ceremony attended by people involved in the project and other guests, the foundation stone was laid for the new Research & Development building at Roche Basel. The project, representing a total investment of approximately 250 million Swiss francs, is an unequivocal expression of the companyâs commitment to the Basel site. At the new facility, R&D work is to be carried out on solid and liquid dosage forms for new active substances.
Amgen's Breakaway from Cancer Initiative Expands to Help Cancer Patients
- Details
- Category: Amgen
In an ongoing effort to raise awareness of the comprehensive continuum of resources available to cancer patients and their caregivers - from prevention to education, patient care to advocacy and financial support - Amgen's Breakaway from Cancer(TM) initiative has expanded its charitable partners to now include the National Coalition for Cancer Survivorship, Patient Advocate Foundation, Prevent Cancer Foundation and The Wellness Community.
Four innovative Novartis medicines approved in Japan
- Details
- Category: Novartis
Patients in Japan stand to benefit from the approval of four innovative medicines - Tasigna® for the treatment of a life-threatening form of leukemia, Xolair® for severe asthma, Co-Dio®[*] for high blood pressure, and Lucentis® for wet age-related macular degeneration (AMD), an eye disease that is a major cause of blindness in people over the age of 50 in Japan.
Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter
- Details
- Category: Abbott
Abbott (NYSE: ABT) has announced financial results for the fourth quarter ended Dec. 31, 2008:
Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results
- Details
- Category: Financial
Johnson & Johnson has announced sales for the year 2008 of $63.7 billion, an increase of 4.3% over 2007. Operational growth was 1.9% with currency contributing 2.4%. Domestic sales decreased 0.4%, while international sales increased 9.7%, reflecting operational growth of 4.6% and a positive currency impact of 5.1%. Worldwide sales in the fourth quarter of 2008 were $15.2 billion, a decrease of 4.9% as compared to the fourth quarter of 2007.
More Pharma News ...
- New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available
- Pfizer Receives FDA Complete Response Letter for Lasofoxifene
- US Department of Health and Human Services awards Novartis USD 486 million contract
- Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
- Nycomed strengthens its osteoporosis portfolio
- U.S. FDA Issues Complete Response Letter for SAPHRIS(TM)
- Abbott Introduces RealTime Molecular Assay in Europe for Detection of HPV Infection